When shares of Optimer (NASDAQ: OPTR) jumped up in February on the news that it was seeking "strategic alternatives" -- in other words, looking for a buyer -- Motley Fool health-care analyst David Williamson warned that the company's defining drug, Dificid, has had slow sales, and finding a buyer might not be easy. However, in this video, David tells investors about an article in Bloomberg, reporting that both GlaxoSmithKline (GSK 2.20%) and AstraZeneca (AZN 2.59%) may be interested, which has shares of Optimer up 20%. David explores what Optimer has to offer that may or may not make this buyout worth the buyer's while.
Is This Really Big Pharma's Next Acquisition?
By Dave Williamson
-
Apr 2, 2013 at 5:14PM
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Where did all this buyout interest come from?
Stocks Mentioned
Merck & Co., Inc.
MRK
$93.55
(1.58%)
$1.46
GlaxoSmithKline plc
GSK
$44.52
(2.20%)
$0.96
AstraZeneca PLC
AZN
$66.21
(2.59%)
$1.67
Cubist Pharmaceuticals LLC
CBST.DL
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Better Buy: Gingko Bioworks vs. Amyris
Have $2,000? 2 Market Crash-Ready Stocks to Buy
Stock Market Plunge: 5 Unstoppable Stocks on Sale to Buy Now and Hold Forever
2 Safe Stocks to Buy in a Bear Market
Tech Stock Sell-Off Got You Scared? Here's a Better Buy.
Motley Fool Returns
Market-beating stocks from our award-winning service.
Stock Advisor Returns
330%
330%
S&P 500 Returns
115%
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Cumulative Growth of a $10,000 Investment in Stock Advisor
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.